Stay up to date with news and events
Hereditary Disease Foundation (HDF) conference 2022 – Day 1
August 31, 2022
Hello and welcome from the HDBuzz team who are currently at the Hereditary Disease Foundation (@hdfcures) 2022 Milton Wexler Biennial Symposium in Boston! It’s the…
Serious side effects reported for some people treated with the huntingtin-lowering drug AMT-130, currently in clinical trials
August 29, 2022
Last month, we relayed positive news from uniQure’s trial testing AMT-130, a gene therapy delivered via brain surgery to lower huntingtin (HTT). Data released by…
Sad news from Novartis: dosing suspended in VIBRANT-HD trial of branaplam
August 10, 2022
The VIBRANT-HD study began in early 2022 and was a long-awaited trial of a huntingtin-lowering drug, branaplam, that could be taken by mouth. On Monday,…
Updates from uniQure about their gene therapy for Huntington’s disease
July 7, 2022
uniQure is a company specializing in gene therapy, and they have been working on an experimental drug for Huntington’s disease (HD), called AMT-130, that is…
Artificial intelligence to save the day? How clever computers are helping us understand Huntington’s disease.
June 21, 2022
Scientists have developed a new model that maps out the different stages of Huntington’s disease (HD) in detail. Using artificial intelligence approaches, the researchers were…